Author

Yue-Yi Sun

h-index 2 View on Semantic Scholar

We have 3 of 8 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Daraxonrasib: The first-in-class RAS(ON) multi-selective inhibitor approved for treatment of metastatic pancreatic adenocarcinoma.

Advanced pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with limited benefits from conventional chemotherapy. Daraxonrasib is an oral, noncovalent RAS(ON) multi-selective inhibitor that forms a ternary complex with cyclophilin A and GTP-bound RAS, blocking downstream signaling across multiple mutant and...

Yue-Yi Sun, Chen Pang, Jian-Jun Gao · Drug Discoveries & Therapeut... · 0 citations

Open access Aug 2026

A machine-learning-derived online prediction model for coronary artery aneurysm risk in children with kawasaki disease: a retrospective cohort study

A machine learning–based prediction model for individualized CAA risk assessment in children with KD has been developed and temporally validated and has been deployed as an online tool to support early risk stratification.

Yiwen Ma, Yue-Yi Sun, Hui Zhang et al. · BMC Pediatrics · 0 citations

Open access Aug 2026

Enlicitide: The first oral PCSK9 inhibitor approved for treatment of hypercholesterolemia.

The ongoing CORALreef Outcomes trial will determine whether enlicitide-mediated LDL-C reduction translates into fewer major cardiovascular events and will help define its long-term clinical role.

Yue-Yi Sun, Jian-Jun Gao · Drug Discoveries & Therapeut... · 0 citations